How CD20-Targeting Rituximab Works as a B-Cell Therapy

Rituximab destroys B cells by latching onto a protein called CD20 that sits on their surface, then triggering the immune system to kill those cells through several overlapping pathways. Approved in 1997 as the first monoclonal antibody for cancer treatment, it has since become one of the most widely used biologic therapies in medicine, spanning blood cancers and autoimmune diseases alike. Its mechanism is not a single on-off switch but a layered assault that recruits the body’s own defenses while also nudging the targeted B cell toward self-destruction.

Why CD20 Makes a Good Target

CD20 is a protein embedded in the outer membrane of B cells. It appears early in B-cell development and stays present through most of the cell’s mature life, but it disappears once a B cell transforms into an antibody-secreting plasma cell. That timing matters. By targeting CD20, rituximab wipes out the B cells that are causing problems while sparing the plasma cells that maintain much of your existing immune memory. Stem cells in the bone marrow also lack CD20, so the body retains the ability to rebuild its B-cell population after treatment.

Structurally, CD20 sits tightly in the membrane as a compact dimer, meaning two CD20 molecules pair together. When rituximab binds, two of its antigen-binding arms each grab one side of that paired CD20 unit, creating a stable complex that does not easily shed from the cell surface.¹ That stability is important because it keeps the drug attached long enough for the killing mechanisms to kick in.

The Four Ways Rituximab Kills B Cells

Rituximab does not rely on a single strategy to eliminate B cells. Research has identified at least four distinct pathways, and they work together. The relative contribution of each pathway varies depending on where the B cell is, how much CD20 it expresses, and what other immune cells are nearby.

Complement-Dependent Cytotoxicity

Once rituximab coats a B cell, it can activate the complement system, a cascade of blood proteins that punches holes in the target cell’s membrane. This process, called complement-dependent cytotoxicity, is particularly sensitive to how densely CD20 is packed on the cell surface. Research has shown a steep, sigmoidal relationship between CD20 expression level and the effectiveness of this pathway: cells with low CD20 levels get relatively little complement killing, while cells above a threshold are destroyed efficiently.² The cascade begins when a complement protein called C1q docks onto the rituximab antibodies clustered on the cell surface, triggering a chain reaction that ultimately tears open the membrane.³

Antibody-Dependent Cellular Cytotoxicity

Natural killer cells are immune cells that patrol the body looking for trouble. When rituximab coats a B cell, the tail end of the antibody sticks out like a flag. Natural killer cells grab that flag through a receptor called CD16, which activates them to release toxic granules that destroy the B cell. This process works alongside complement killing but is not dependent on how much CD20 the cell displays in the same steep way.² Interestingly, the complement system and this natural-killer-cell pathway can actually interfere with each other. When complement proteins coat the B cell, they can block the CD16 receptor on natural killer cells, dampening their activation.⁴ This is one reason the overall effectiveness of rituximab is not simply the sum of its individual mechanisms.

Macrophage Phagocytosis

While complement and natural killer cells get much of the attention, animal studies have pointed to macrophages as perhaps the most important effector in vivo. Macrophages are immune cells that engulf and digest debris. When they encounter a rituximab-coated B cell, they swallow it whole in a process called antibody-dependent cellular phagocytosis. Mouse studies have found that this phagocytic clearance accounts for substantially more B-cell depletion than natural-killer-cell killing, with one study reporting that the per-cell killing rate through phagocytosis was at least tenfold greater than through the natural-killer-cell pathway.⁵ This mechanism has been recognized as a major driver of anti-CD20 therapy across several widely used antibodies.⁶

Direct Signaling and Programmed Cell Death

Even without any help from the immune system, rituximab binding to CD20 can trigger changes inside the B cell that push it toward death. When rituximab attaches and is cross-linked on the cell surface, it activates internal signaling pathways involving enzymes called kinases and caspases. These are the cell’s own self-destruct machinery. Researchers have documented that rituximab modifies structures in the cell membrane called lipid rafts, activates stress-signaling pathways, and shifts the balance between pro-survival and pro-death signals inside the cell.⁷ One key pathway involves a stress-response enzyme called p38 MAP kinase; blocking that enzyme in laboratory experiments significantly reduced rituximab-induced cell death.⁸ More recent work using genetic screening techniques has identified specific signaling proteins that act as gatekeepers for this direct death signal, suggesting the pathway is tightly intertwined with the B cell’s normal growth-and-survival wiring.⁹

Treating Blood Cancers

Rituximab’s original and still most prominent use is in B-cell cancers, especially non-Hodgkin lymphoma and chronic lymphocytic leukemia. Since its initial approval, it has improved outcomes across these diseases.¹⁰ The drug is almost never used alone in aggressive cancers. Instead, it is combined with chemotherapy regimens. The most common combination, known as R-CHOP, pairs rituximab with four chemotherapy drugs and has been the standard of care for diffuse large B-cell lymphoma for two decades, curing roughly 70% of cases.¹¹

Adding rituximab to chemotherapy was transformative when it first happened. Early randomized trials comparing CHOP chemotherapy alone with R-CHOP showed a clear survival benefit, and the improvement in elderly patients with aggressive lymphoma was particularly striking, representing the first statistical improvement over standard chemotherapy in two decades at the time.¹² In follicular lymphoma, a slower-growing cancer, rituximab has been approved both as part of initial treatment in combination with chemotherapy and as maintenance therapy to keep the disease in remission after other treatments.¹³

Expanding Into Autoimmune Diseases

The logic behind using rituximab in autoimmune disease is straightforward: if your immune system is attacking your own tissues because B cells are producing harmful autoantibodies or driving inflammation, depleting those B cells should quiet the attack. This approach has worked in practice. Rituximab is approved for rheumatoid arthritis and has been used off-label in a growing list of autoimmune conditions.¹⁴

In rheumatoid arthritis, rituximab works by depleting the B cells that produce the autoantibodies driving joint inflammation and tissue damage. That depletion reduces inflammatory signaling and breaks the cycle of immune-mediated tissue destruction.¹⁵ Early-phase trials also confirmed benefit in Sjögren’s syndrome, vasculitis, and immune thrombocytopenic purpura, broadening the evidence base for its use in B-cell-mediated autoimmune conditions beyond its approved indications.¹⁶ In multiple sclerosis, rituximab has been used off-label with enough success that its mechanism inspired the development of newer anti-CD20 drugs specifically approved for MS, like ocrelizumab.

What Happens After B Cells Are Depleted

Rituximab depletes the vast majority of circulating B cells quickly, with counts dropping by a mean of about 97% within the first few months. All B-cell subsets are affected, though a small residual population survives, mostly composed of memory B cells and plasma cell precursors.¹⁷

B-cell recovery follows a predictable sequence. The first cells to reappear are immature B cells freshly produced from the bone marrow. Naive B cells follow shortly after and eventually dominate the recovering pool. Memory B cells, the experienced cells that remember past infections, recover much more slowly and can remain significantly reduced for over two years after treatment.¹⁸ In a pediatric cohort, about half of patients remained depleted at six months, and while most had some detectable B cells by twelve months, nearly half were still below normal levels at that point.¹⁹

This slow, staged recovery has real implications. The delay in memory B-cell repopulation is one reason rituximab can produce long-lasting remissions in autoimmune diseases: the freshly rebuilt B-cell population may not immediately develop the same self-attacking tendencies. But the slow rebound also means the window of immune vulnerability after treatment can last many months.

Risks and Side Effects

The most common acute reaction during rituximab infusion is a cluster of symptoms caused by the rapid release of inflammatory signals as B cells are destroyed. Fever, chills, drops in blood pressure, and sometimes difficulty breathing can occur, especially during the first infusion when the B-cell burden is highest. In rare cases, this can escalate into a full cytokine release syndrome, though that outcome is uncommon.²⁰ Infusion reactions are managed by slowing the infusion rate and pre-medicating with drugs like acetaminophen, antihistamines, and sometimes corticosteroids. Most patients tolerate subsequent infusions better.

The longer-term concern is infection. Depleting B cells weakens one arm of the immune system, and repeated treatment cycles can drive down immunoglobulin levels over time, a condition called hypogammaglobulinemia. Vaccination responses are also blunted while B cells are depleted. Guidelines generally recommend timing vaccines five to twelve months after the last rituximab course and at least four weeks before the next, though that window is not always practical.²¹ The COVID-19 pandemic made this vulnerability impossible to ignore. Studies found that only about 29% of rituximab-treated patients with autoimmune diseases developed neutralizing antibodies after vaccination, compared with roughly 80-92% in comparison groups, and none of the patients who had received rituximab in the prior six months responded at all.²²

Two specific infectious complications deserve mention. Hepatitis B virus can reactivate in patients who carry the virus, even if it was previously controlled. This risk is serious enough that screening for hepatitis B before starting rituximab is now standard practice, with antiviral prophylaxis recommended for carriers.²³ The other, rarer complication is progressive multifocal leukoencephalopathy, a devastating brain infection caused by a virus called JC virus. A review of 57 reported cases found a 90% fatality rate, with a median time from the last rituximab dose to diagnosis of about five and a half months. Most of those patients had also received other immunosuppressive treatments, making it difficult to assign blame to rituximab alone, but the risk is real enough to warrant awareness.²⁴

Intravenous Versus Subcutaneous Delivery

Rituximab was originally given only as an intravenous infusion, which typically takes two to three hours and requires a clinic chair and monitoring. A subcutaneous formulation was later developed, combining rituximab with an enzyme called hyaluronidase that helps the drug spread under the skin. Randomized trials in both follicular lymphoma and diffuse large B-cell lymphoma have shown that the subcutaneous version works just as well as the intravenous form, with similar response rates and comparable side-effect profiles.²⁵²⁶

The practical advantages are significant. The subcutaneous injection takes about six minutes compared with several hours. Patients spend less time at the hospital, report better convenience scores, and experience less disruption to daily life. The trade-off is a higher rate of minor injection-site reactions like redness or swelling at the injection spot. For patients who need repeated infusions over months or years, as is common in both cancer maintenance and autoimmune disease, the time savings add up considerably.

How Newer Anti-CD20 Drugs Compare

Rituximab was the pioneer, but it is not the only anti-CD20 antibody anymore. Obinutuzumab, a newer drug, was engineered with modifications that change the balance of its killing mechanisms. It induces stronger direct cell death through different signaling activity and produces more potent macrophage-mediated killing. Phosphoproteomic studies have shown that while both antibodies activate some of the same internal pathways in B cells, obinutuzumab drives more aggressive pro-death signaling through a kinase called SYK, whereas rituximab paradoxically activates some pro-survival signals through pathways like AKT and NOTCH1 that can reinforce resistance to cell death.²⁷

This matters clinically in diseases where rituximab has fallen short. In systemic lupus erythematosus and lupus nephritis, rituximab has been used off-label for over two decades, but two pivotal randomized trials failed to meet their primary endpoints. Obinutuzumab achieves deeper and more durable B-cell depletion in part because the target cell is less able to shed or internalize the antibody, a phenomenon called antigenic modulation that can limit rituximab’s effectiveness.²⁸ Understanding where rituximab’s mechanism has weaknesses has been essential for designing these next-generation agents.

Biosimilars and the Cost Landscape

Rituximab was the top-selling cancer drug in the world for nearly a decade, with global sales reaching $8.58 billion in 2016.¹⁰ Since the original patent expired, multiple biosimilar versions have entered the market. These are near-copies of the original drug, manufactured by different companies and approved based on demonstrating equivalent clinical performance. Their entry has driven down costs meaningfully. Between 2019 and 2022, total Medicare Part B spending on all rituximab products dropped from $1.7 billion to $1.0 billion, a 40% reduction. Across Medicare and Medicaid combined, the savings totaled about $728 million by 2022 compared with 2019 spending levels.²⁹

Biosimilar uptake has varied internationally. A budget-impact analysis from Qatar projected cumulative five-year savings of over seven million Qatari riyals for non-Hodgkin lymphoma patients alone when switching from the reference product to a biosimilar, with per-patient savings of about 9,000 QAR per treatment course.³⁰ For a drug given repeatedly over months to years, these savings translate directly into broader access. In resource-constrained settings, biosimilar availability can be the difference between a patient receiving anti-CD20 therapy or not receiving it at all.